Prevail Innovative Wealth Advisors’s AbbVie ABBV Stock Holding History

Prevail Innovative Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$437K	Buy	1,737 +744	+75%	+$160K	0.07%	135
2026 Q1	$216K	Sell	993 -6,169	-86%	-$1.37M	0.04%	172
2025 Q4	$1.64M	Buy	7,162 +533	+8%	+$121K	0.29%	119
2025 Q3	$1.53M	Buy	6,629 +1,987	+43%	+$405K	0.3%	129
2025 Q2	$862K	Buy	4,642 +254	+6%	+$47.2K	0.19%	143
2025 Q1	$919K	Buy	4,388 +2,456	+127%	+$477K	0.24%	110
2024 Q4	$343K	Buy	1,932 +700	+57%	+$129K	0.1%	136
2024 Q3	$243K	Buy	+1,232	New	+$230K	0.07%	147

Other funds holding ABBV

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Prevail Innovative Wealth Advisors's ABBV Position: Q2 2026 in Review

Prevail Innovative Wealth Advisors increased its AbbVie (ABBV) stake by 75% in Q2 2026, buying an estimated $160K and bringing the position to 1,737 shares worth $437K. The position accounts for 0.07% of the portfolio, ranked #135.

Prevail Innovative Wealth Advisors first reported a position in ABBV in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.64M in Q4 2025. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Prevail Innovative Wealth Advisors held 1,737 shares of AbbVie worth $437K as of Q2 2026.
Prevail Innovative Wealth Advisors bought 744 AbbVie shares in Q2 2026, an estimated $160K.
AbbVie made up 0.07% of Prevail Innovative Wealth Advisors's portfolio in Q2 2026, its #135 holding.
Prevail Innovative Wealth Advisors first reported a position in AbbVie in Q3 2024 and has held it in 8 quarters since.
Prevail Innovative Wealth Advisors's AbbVie position peaked at $1.64M in Q4 2025.
2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Prevail Innovative Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.